Skip to main content

Advertisement

SpringerLink
Log in

Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

In a step-up approach of DMARD treatment of RA a fast response and an early DMARD switch in the case of non-response is important. Therefore, we performed an open trial in which we compared an 8-week and a 16-week observation period during treatment of RA with MTX or LEF, both given in intensified starting doses and accompanied by moderate dose prednisone. MTX and LEF naïve patients with RA (mean time since diagnosis: 2.3 years) were randomised to receive either LEF in a 3-day-loading dose of 100 mg/day followed by 20 mg/day (n = 19) or MTX intramuscularly in a dose of 25 mg once weekly (n = 21). All patients received concomitant treatment with oral prednisone in an initial dose of 20 mg/day with weekly dose reductions of 5 mg/day. The disease activity was re-evaluated 8 and 16 weeks after the start of the treatment. Mean DAS28 before the start of treatment was 5.36 ± 0.8 for the MTX-group and 5.46 ± 0.8 for the LEF-group. After 8 weeks of treatment the DAS28 in the MTX-group was 2.59 ± 1.0 and 3.16 ± 0.8 in the LEF group (difference not significant). The mean DAS28 at re-evaluation 16 weeks after the starting of treatment (2.58 ± 1.5 for the MTX-group and 3.25 ± 1.16 for the LEF-group) was significantly different neither in between the both treatment groups nor in comparison to the week 8 evaluation. Efficiency of RA treatment with MTX or LEF in intensified doses and in combination with moderate dose prednisone can be sufficiently judged 8 weeks after its initiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zink A, Listing J, Niewerth M, Zeidler H (2001) The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 60:207–213

    Article  PubMed  CAS  Google Scholar 

  2. Thiele K, Buttgereit F, Huscher D, Zink A (2005) German collaborative arthritis centres. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum 53:740–747

    Article  PubMed  CAS  Google Scholar 

  3. O’Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164–1170

    Article  PubMed  CAS  Google Scholar 

  4. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, Luggen ME, Keystone E, Weisman MH, Bensen WM, Kaine JL, Ruderman EM, Coleman P, Curtis DL, Kopp EJ, Kantor SM, Waltuck J, Lindsley HB, Markenson A, Strand V, Crawford B, Fernando I, Simpson K, Bathon JM (2002) Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137:726–733

    PubMed  CAS  Google Scholar 

  5. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate–Cyclosporine Combination Study Group. N Engl J Med 333:137–141

    Article  PubMed  CAS  Google Scholar 

  6. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Dougados M (2003) Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 62(suppl II):ii2–ii9

    PubMed  Google Scholar 

  7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  PubMed  CAS  Google Scholar 

  8. van Gestel AM, Prevoo ML, ‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:34–40

    Article  PubMed  Google Scholar 

  9. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Kincaid W, Porter D (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364:263–269

    Article  PubMed  Google Scholar 

  10. Schnabel A, Herlyn K, Burchardi C, Reinhold-Keller E, Gross WL (1996) Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int 15:195–200

    Article  PubMed  CAS  Google Scholar 

  11. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I (1998) Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 16:313–320

    Google Scholar 

  12. Gabriel S, Creagan E, O’Fallon WM, Jaquith J, Bunch T (1990) Treatment of rheumatoid arthritis with higher dose intravenous methotrexate. J Rheumatol 17:460–465

    PubMed  CAS  Google Scholar 

  13. Shiroky JB, Neville C, Skelton JD (1992) High dose intravenous methotrexate for refractory rheumatoid arthritis. J Rheumatol 19:247–251

    PubMed  CAS  Google Scholar 

  14. Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W, Pichlmeier U, Brandt A (2005) The clinical efficacy and safety of subcutaneous (s.c.) versus oral application of methotrexate (MTX) in patients with active rheumatoid arthritis (RA)—results of a randomized, controlled, double-blind, multi-center study. Arthritis Rheum 52(Suppl):ii542

    Google Scholar 

  15. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 353:259–266

    Article  PubMed  CAS  Google Scholar 

  16. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V (2001) Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 44:1984–1992

    Article  PubMed  CAS  Google Scholar 

  17. Wassenberg S, Rau R, Steinfeld P, Zeidler H (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 52:3371–3380

    Article  PubMed  CAS  Google Scholar 

  18. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, van der Brink HR, Schouten HJ, van der Heijde DM, Boonen A, van der Linden S (1997) Randomized comparison of combined Stepp-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318

    Article  PubMed  CAS  Google Scholar 

  19. Fiehn C, Rochel E, Ho AD, Max R (2004) Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with RA and insufficient response to standard dose LEF. Ann Rheum Dis 63:746–747

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was sponsored by a grant from MEDAC.

Author information

Authors and Affiliations

  1. Association of Rheumatologists (Berufsverband der Rheumatologen), Baden-Württemberg, Germany

    C. Fiehn, S. Jacki, B. Heilig, M. Lampe, G. Wiesmüller, C. Richter, E. Röther & I. Gao

  2. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany

    C. Fiehn & E. Rochel

  3. Centre for Rheumatic Diseases, Rotenbachtalstr. 5, 76530, Baden-Baden, Germany

    C. Fiehn

Authors
  1. C. Fiehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Jacki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Heilig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lampe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Wiesmüller
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Röther
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Rochel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. I. Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Fiehn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiehn, C., Jacki, S., Heilig, B. et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. Rheumatol Int 27, 975–979 (2007). https://doi.org/10.1007/s00296-007-0347-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-007-0347-0

Keywords

Search

Navigation